FACT-MNG: Tumor site specific web-based outcome instrument for meningioma patients

D. Zlotnick, S. N. Kalkanis, A. Quinones-Hinojosa, K. Chung, M. E. Linskey, R. L. Jensen, F. Demonte, F. G. Barker, C. A. Racine, M. S. Berger, P. M. Black, M. Cusimano, L. N. Sekhar, A. Parsa, M. Aghi, Michael W. McDermott

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


To formulate Functional Assessment of Cancer Therapy-Meningioma (FACT-MNG), a web-based tumor site-specific outcome instrument for assessing intracranial meningioma patients following surgical resection or stereotactic radiosurgery. We surveyed the relevant literature available on intracranial meningioma surgery and subsequent outcomes (38 papers), making note of which, if any, QOL/outcome instruments were utilized. None of the surgveyed papers included QOL assessment specific to tumor site. We subsequently developed questions that were relevant to the signs and symptoms that characterize each of 11 intracranial meningioma sites, and incorporated them into a modified combination of the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and SF36 outcome instruments, thereby creating a new tumor site-specific outcome instrument, FACT-MNG. With outcomes analysis of surgical and radiosurgical treatments becoming more important, measures of the adequacy and success of treatment are needed. FACT-MNG represents a first effort to formalize such an instrument for meningioma patients. Questions specific to tumor site will allow surgeons to better assess specific quality of life issues not addressed in the past by more general questionnaires.

Original languageEnglish (US)
Pages (from-to)423-431
Number of pages9
JournalJournal of neuro-oncology
Issue number3
StatePublished - Sep 2010
Externally publishedYes


  • Intracranial surgery
  • Meningioma
  • Quality of life
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'FACT-MNG: Tumor site specific web-based outcome instrument for meningioma patients'. Together they form a unique fingerprint.

Cite this